Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.31 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954903 | 1.00 | ERN1 (0.35) | ERN1POLBCASP6TDP1ALDH1A1 | |
| SCHEMBL29952308 | 0.83 | ERN1 (0.35) | ERN1POLBCASP6TDP1KCNQ3 | |
| SCHEMBL898922 | 0.83 | ERN1 (0.35) | ERN1POLBCASP6TDP1KCNQ3 | |
| SCHEMBL26984273 | 0.79 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL24086588 | 0.78 | ERN1 (0.38) | ERN1POLBCASP6 | |
| SCHEMBL1533918 | 0.78 | TDP1 (0.40) | ERN1TDP1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30589401 | 0.78 | TDP1 (0.40) | ERN1TDP1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6856975 | 0.75 | ERN1 (0.34) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1389512 | 0.75 | ERN1 (0.48) | ERN1POLBTDP1ALDH1A1 | |
| SCHEMBL9938111 | 0.75 | ERN1 (0.41) | ERN1TDP1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| CN-114423750-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | ADVNET PHARMA CO. LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| WO-2009143018-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| EP-2051990-A1 | SMAC PEPTIDOMIMETICS USEFUL AS IAP INHIBITORS | Novartis AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| WO-2008016893-A1 | SMAC PEPTIDOMIMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016893-A1 | SMAC PEPTIDOMIMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007016358-A1 | N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | ERN1 2560/4885POLB 3834/4885CASP6 3067/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | ERN1 2560/4885POLB 3834/4885CASP6 3067/4885 |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | ERN1 2308/4885POLB 2561/4885CASP6 2128/4885 |
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | SHBG, AR, NR5A1 | ERN1 4310/4885POLB 520/4885CASP6 4453/4885 |
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR4, FGFR2 | ERN1 3952/4885POLB 4403/4885CASP6 3823/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | ERN1 1480/4885POLB 3690/4885CASP6 248/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | ERN1 527/4885POLB 1212/4885CASP6 2651/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | ERN1 1013/4885POLB 4570/4885CASP6 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.